Synopsis: Panacea Biotec Ltd shares rose 15% upon launching DENSTAR, a four-year global initiative with EU-funded EDCTP3 support to advance licensing, trials, and access of dengue vaccine DengiAll®, including Phase 1/3 studies in Africa, CHIM evaluation, and efforts to enable single-dose scalable immunisation without prior serology and global deployment.
The shares of a Small-Cap company, which specialises in the research, development, and manufacturing of innovative vaccines, complex generic pharmaceuticals, biosimilars, and nutraceuticals, are in focus upon the launch of the DENSTAR project, which will work to advance the licensure of the dengue vaccine DengiAll®.
With a market capitalization of Rs. 3,791.42 crores in the day’s trade, the shares of Panacea Biotec Ltd rose upto 14.5. percent, making a high of Rs. 633.35 per share compared to its previous closing price of Rs. 553.25 per share.
What Happened
Panacea Biotec has announced the launch of the DENSTAR project, a four-year initiative aimed at advancing the licensure and global access of its tetravalent dengue vaccine, DengiAll®. The project focuses on expanding vaccine availability in sub-Saharan Africa (sSA) and supporting broader global use to reduce dengue disease burden.
Funding and Coordination
The project is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union. It is coordinated by the Sclavo Vaccines Association, a non-profit organisation based in Siena, Italy, dedicated to supporting vaccine research and development in developing countries.
Consortium and Global Collaboration
DENSTAR brings together 10 partners from 9 countries across Europe, Africa, the United States, India, and South Korea. The consortium includes universities, research institutions, a biotech company, and non-profit organisations. Panacea Biotec, the developer of DengiAll®, plays a key role in this public-private partnership aimed at improving equitable access to dengue prevention tools.
Disease Background and Need
Dengue is a rapidly increasing global health threat, especially in Africa, where outbreaks are rising but underreported. Severe cases can cause life-threatening complications, and there is currently no specific antiviral treatment. Existing prevention methods and vaccines provide only partial protection, highlighting the urgent need for a safe and effective vaccine.
Clinical Development Activities
The DENSTAR project will conduct Phase 1/3 clinical studies in healthy adults and children in Africa to evaluate the safety and efficacy of DengiAll®. It will also use Controlled Human Infection Models (CHIMs) to assess protection against Dengue Virus serotype 4 (DENV-4), strengthening scientific evidence for regulatory approval and wider deployment.
DengiAll® is designed as a single-dose, cost-efficient, and scalable vaccine suitable for large-scale immunisation programs. It does not require prior serological testing, making it easier to deploy across diverse populations. These features make it particularly suitable for low- and middle-income countries.
The overall goal of DENSTAR is to support regulatory licensure and facilitate global access to DengiAll®, contributing to equitable dengue prevention and reduced disease burden in Africa and beyond.
Can Panacea Biotec’s DengiAll® Become the Game-Changer?
Panacea Biotec’s DengiAll® can be considered a potential “game-changer” against dengue because it is designed to overcome key limitations of existing prevention tools. As a single-dose tetravalent vaccine that does not require prior serological testing, it offers a simpler, more scalable solution for large immunisation programs. This makes it especially valuable for low- and middle-income regions where dengue is rising rapidly and healthcare systems often struggle with multi-dose schedules and screening requirements.
The DENSTAR project further strengthens its impact by advancing Phase 1/3 clinical trials and Controlled Human Infection Model studies across multiple countries, including in Africa, where dengue is underreported but increasing. Backed by international collaboration and EU funding, the initiative focuses on regulatory approval and equitable global access. If successful, DengiAll® could significantly improve dengue prevention by enabling wider, faster, and more practical vaccine deployment worldwide.
Financials & Others
The company’s revenue rose by 25.82 percent from Rs. 132.53 crores in March 2025 to Rs. 166.75 crores in March 2026. Meanwhile, Net loss declined from Rs. 1.99 crores to Rs. 1.00 crores in the same period.
Panacea Biotec is a leading biotechnology company with strong capabilities in research, manufacturing, and marketing. It has played a significant role in India’s polio eradication efforts by supplying over 10 billion doses of oral polio vaccines. Over the years, the company has expanded its impact across infectious diseases, focusing on innovative vaccine development and large-scale global distribution.
Its vaccine portfolio also includes Easyfive-TT, EasyFour-TT, EasyFour-Pol, and bivalent oral polio vaccines, with several advanced candidates such as pneumococcal and dengue vaccines in the pipeline.
In addition to vaccines, Panacea Biotec has launched its consumer healthcare arm, 7N Panacea Biotec, focused on everyday health solutions. Built on the “7N” philosophy, Nutrition, Nurture, Nature, Newness, Novelty, Necessity, and Nourishment—the brand offers nutritional and baby care products such as ChilRun, NikoMom, and Staart infant formula, aiming to deliver safe, science-driven, and affordable healthcare for families.
In conclusion, Panacea Biotec’s DengiAll® shows strong potential to become a meaningful breakthrough in dengue prevention, particularly due to its single-dose design, tetravalent protection, and ease of large-scale deployment without prior serological testing. The launch of the DENSTAR project, backed by international collaboration and EU funding, further strengthens its pathway toward regulatory approval and global access.
However, its ultimate impact will depend on the success of ongoing clinical trials and real-world effectiveness across diverse populations. If these outcomes are positive, DengiAll® could significantly improve global dengue control, especially in high-burden, resource-limited regions.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
